156 related articles for article (PubMed ID: 22002244)
41. An investigation of reversal of imatinib resistance in the Bcr-Abl positive imatinib-resistant cell line K562r by dasatinib, nilotinib, rapamycin and bortezomib.
Xing H; Liu T; Meng W; Gong Y
Int J Lab Hematol; 2011 Apr; 33(2):176-81. PubMed ID: 20942869
[TBL] [Abstract][Full Text] [Related]
42. Sensitization of imatinib-resistant CML cells to TRAIL-induced apoptosis is mediated through down-regulation of Bcr-Abl as well as c-FLIP.
Park SJ; Kim MJ; Kim HB; Kang CD; Kim SH
Biochem J; 2009 Apr; 420(1):73-81. PubMed ID: 19203346
[TBL] [Abstract][Full Text] [Related]
43. Valproate enhances imatinib-induced growth arrest and apoptosis in chronic myeloid leukemia cells.
Morotti A; Cilloni D; Messa F; Arruga F; Defilippi I; Carturan S; Catalano R; Rosso V; Chiarenza A; Pilatrino C; Guerrasio A; Taulli R; Bracco E; Pautasso M; Baraban D; Gottardi E; Saglio G
Cancer; 2006 Mar; 106(5):1188-96. PubMed ID: 16444746
[TBL] [Abstract][Full Text] [Related]
44. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
45. Synergistic killing effect of imatinib and simvastatin on imatinib-resistant chronic myelogenous leukemia cells.
Oh B; Kim TY; Min HJ; Kim M; Kang MS; Huh JY; Kim Y; Lee DS
Anticancer Drugs; 2013 Jan; 24(1):20-31. PubMed ID: 23075630
[TBL] [Abstract][Full Text] [Related]
46. Myc induced miR-144/451 contributes to the acquired imatinib resistance in chronic myelogenous leukemia cell K562.
Liu L; Wang S; Chen R; Wu Y; Zhang B; Huang S; Zhang J; Xiao F; Wang M; Liang Y
Biochem Biophys Res Commun; 2012 Aug; 425(2):368-73. PubMed ID: 22842456
[TBL] [Abstract][Full Text] [Related]
47. Diverse mechanisms of mTOR activation in chronic and blastic phase of chronic myelogenous leukemia.
Stoklosa T; Glodkowska-Mrowka E; Hoser G; Kielak M; Seferynska I; Wlodarski P
Exp Hematol; 2013 May; 41(5):462-9. PubMed ID: 23395818
[TBL] [Abstract][Full Text] [Related]
48. [Growth inhibition and differentiation of imatinib-resistant chronic myeloid leukemia cell induced by cell differentiation agent in vitro].
Wang XD; Qiu L; Lu RZ; Chen LJ; Zhan ZM; Han BH; Zhang BL; Ma J
Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(48):3399-405. PubMed ID: 18476538
[TBL] [Abstract][Full Text] [Related]
49. Effect of imatinib mesylate combined with granulocyte colony-stimulating factor on leukaemic blast cells derived from advanced-stage chronic myelogenous leukaemia patients.
Ota S; Musashi M; Kondo K; Toyoshima N; Toubai T; Onozawa M; Mori A; Hashino S; Tanaka J; Matsuno K; Imamura M; Asaka M
Acta Haematol; 2006; 116(1):8-18. PubMed ID: 16809884
[TBL] [Abstract][Full Text] [Related]
50. RPS27a promotes proliferation, regulates cell cycle progression and inhibits apoptosis of leukemia cells.
Wang H; Yu J; Zhang L; Xiong Y; Chen S; Xing H; Tian Z; Tang K; Wei H; Rao Q; Wang M; Wang J
Biochem Biophys Res Commun; 2014 Apr; 446(4):1204-10. PubMed ID: 24680683
[TBL] [Abstract][Full Text] [Related]
51. [Effect of bortezomib on the drug sensitivity of imatinib resistant K562/G01 cells].
Zhou Y; Ma LM; Li XY; Zhang HP; Wang T; Niu YY; Ren RR
Zhonghua Xue Ye Xue Za Zhi; 2011 Jun; 32(6):392-5. PubMed ID: 21781497
[TBL] [Abstract][Full Text] [Related]
52. 5'-OH-5-nitro-Indirubin oxime (AGM130), an Indirubin derivative, induces apoptosis of Imatinib-resistant chronic myeloid leukemia cells.
Kim WS; Lee MJ; Kim DH; Lee JE; Kim JI; Kim YC; Song MR; Park SG
Leuk Res; 2013 Apr; 37(4):427-33. PubMed ID: 23337400
[TBL] [Abstract][Full Text] [Related]
53. Docetaxel enhances the cytotoxic effects of imatinib on Philadelphia positive human chronic myeloid leukemia cells.
Gucluler G; Baran Y
Hematology; 2009 Jun; 14(3):139-44. PubMed ID: 19490758
[TBL] [Abstract][Full Text] [Related]
54. Combining nilotinib and imatinib improves the outcome of imatinib-resistant blast phase CML.
Zhu GR; Ji O; Ji JM; Zhang YC; Wu Y; Yu H; Jiang PJ; Shen Q
Acta Haematol; 2012; 127(3):152-5. PubMed ID: 22286512
[TBL] [Abstract][Full Text] [Related]
55. Bortezomib-mediated downregulation of S-phase kinase protein-2 (SKP2) causes apoptotic cell death in chronic myelogenous leukemia cells.
Iskandarani A; Bhat AA; Siveen KS; Prabhu KS; Kuttikrishnan S; Khan MA; Krishnankutty R; Kulinski M; Nasr RR; Mohammad RM; Uddin S
J Transl Med; 2016 Mar; 14():69. PubMed ID: 26956626
[TBL] [Abstract][Full Text] [Related]
56. Zoledronate inhibits proliferation and induces apoptosis of imatinib-resistant chronic myeloid leukaemia cells.
Chuah C; Barnes DJ; Kwok M; Corbin A; Deininger MW; Druker BJ; Melo JV
Leukemia; 2005 Nov; 19(11):1896-904. PubMed ID: 16167056
[TBL] [Abstract][Full Text] [Related]
57. Pilot study of bortezomib for patients with imatinib-refractory chronic myeloid leukemia in chronic or accelerated phase.
Santos FP; Kantarjian H; McConkey D; O'Brien S; Faderl S; Borthakur G; Ferrajoli A; Wright J; Cortes J
Clin Lymphoma Myeloma Leuk; 2011 Aug; 11(4):355-60. PubMed ID: 21816374
[TBL] [Abstract][Full Text] [Related]
58. Hypoxia selects bortezomib-resistant stem cells of chronic myeloid leukemia.
Tanturli M; Giuntoli S; Barbetti V; Rovida E; Dello Sbarba P
PLoS One; 2011 Feb; 6(2):e17008. PubMed ID: 21347297
[TBL] [Abstract][Full Text] [Related]
59. The roles of macromolecules in imatinib resistance of chronic myeloid leukemia cells by Fourier transform infrared spectroscopy.
Baran Y; Ceylan C; Camgoz A
Biomed Pharmacother; 2013 Apr; 67(3):221-7. PubMed ID: 23433849
[TBL] [Abstract][Full Text] [Related]
60. Relationship between elevated levels of the alpha 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis and pharmacological resistance to imatinib (Gleevec) in vitro and in vivo.
Larghero J; Leguay T; Mourah S; Madelaine-Chambrin I; Taksin AL; Raffoux E; Bastie JN; Degos L; Berthaud P; Marolleau JP; Calvo F; Chomienne C; Mahon FX; Rousselot P
Biochem Pharmacol; 2003 Nov; 66(10):1907-13. PubMed ID: 14599548
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
